Search

Displaying results 6101 - 6110 of 10000 in total
  1. Drug

    Meticrane

    go.drugbank.com/drugs/DB13284
    Approved

    It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647].

  2. Drug

    Lexaptepid pegol

    go.drugbank.com/drugs/DB12578
    Investigational

    Lexaptepid pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases, End Stage Renal Disease, and Anemia of Chronic Disease.

  3. Drug

    Dopexamine

    go.drugbank.com/drugs/DB12313
    ApprovedWithdrawn

    Dopexamine has been used in trials studying the diagnostic and treatment of Free Flap, Oral Cancer, Hypotension, Septic Shock, and Head and Neck Cancer.

  4. Drug

    Morus alba root bark

    go.drugbank.com/drugs/DB14271
    Investigational

    Morus alba root bark is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  5. Drug

    Magnolia kobus flowering top

    go.drugbank.com/drugs/DB14319
    Investigational

    Magnolia kobus flowering top is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  6. Drug

    Zanthoxylum clava-herculis bark

    go.drugbank.com/drugs/DB14379
    Experimental

    Zanthoxylum clava-herculis bark is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  7. Drug

    VM4-037

    go.drugbank.com/drugs/DB15319
    Investigational

    VM4-037 is under investigation in clinical trial NCT00884520 (An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037).

  8. Drug

    Glafenine

    go.drugbank.com/drugs/DB08963
    ApprovedWithdrawn

    An anthranilic acid derivative with analgesic properties used for the relief of all types of pain. Glafenine is withdrawn from the American market.

  9. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

  10. Drug

    Seproxetine

    go.drugbank.com/drugs/DB06731
    Experimental

    It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.